Biomarker-driven trial in metastatic pancreas cancer: Feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

Cancer Medicine

Volumn 1, Issue 2, 2012, Pages 207-217

  Arcaroli, John ^a   Quackenbush, Kevin ^a   Dasari, Arvind ^b   Powell, Rebecca ^a   McManus, Martine ^a   Tan, Aik Choon ^a   Foster, Nathan R ^c   Picus, Joel ^d   Wright, John ^e   Nallapareddy, Sujatha ^a   Erlichman, Charles ^c   Hidalgo, Manuel ^f   Messersmith, Wells A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Cancer Therapy Evaluation Program   (United States)

^f Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Biomarker; Clinical trial; Pancreas cancer; Src

Indexed keywords

LEUCINE RICH REPEAT CONTAINING PROTEIN 19; PIK3CA PROTEIN; SARACATINIB; SOMATOMEDIN BINDING PROTEIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT INFECTION; BLOODSTREAM INFECTION; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE MARKER; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; GALLBLADDER PERFORATION; GENE; HUMAN; HUMAN TISSUE; HYPONATREMIA; HYPOXIA; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY ASPIRATION; RESPIRATORY FAILURE; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR BIOPSY; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

EID: 84891834907     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.27     Document Type: Article

References (39)

1. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61:69-90.
2. Yeo, T. P., R. H. Hruban, S. D. Leach, et al. 2002. Pancreatic cancer. Current Problems in Cancer 26:176-275.
3. Burris, H. A., III, M. J. Moore, J. Andersen, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15:2403-2413.
4. Conroy, T., F. Desseigne, M. Ychou, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine 364:1817-1825.
5. Irby, R., and T. Yeatman. 2000. Role of Src expression and activation in human cancer. Oncogene 19:5636-5642.
6. Avizienyte, E., and M. Frame. 2005. Src and FAK signaling controls adhesion fate and the epithelial-to-mesenchymal transition. Current Opinion in Cell Biology 17:547-547.
7. Hauck, C., D. Hsia, and D. Schlaepfer. 2002. The focal adhesion kinase: a regulator of cell migration and invasion. IUBMB Life 53:115-119.
8. Niu, G., K. Wright, M. Huang, et al. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008.
9. Schaller, M. D. 2001. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochimica et Biophysica Acta 1540:1-21.
10. Yu, C., D. Meyer, G. Cambpell, et al. 1995. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83.
11. Bolen, J., A. Veillette, A. Schwartz, V. Deseau, and N. Rosen. 1987. Analysis of pp 60c-src activation in human colon carcinoma and normal human colon mucosal cells. Oncogene 1:149-168.
12. Green, T. P., M. Fennell, R. Whittaker, et al. 2009. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology 3:248-261.
13. Mazurenko, N., E. Kogan, I. Zborovskaya, and F. Kisseljov. 1992. Expression of pp 60c-src in human small cell and non-small cell lung carcinomas. European Journal of Cancer 28:372-377.
14. Tan, M., P. Li, K. Klos, et al. 2005. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research 65:1858-1867.
15. Zhang, S., W. C. Huang, P. Li, et al. 2011. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine 17:461-469.
16. Trevino, J., J. Summy, D. Lesslie, et al. 2006. Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. American Journal of Pathology 168:962-972.
17. Rajeshkumar, N. V., A. C. Tan, E. De Oliveira, et al. 2009. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clinical Cancer Research 15:4138-4146.
18. Neri, D., and R. Bicknell. 2005. Tumour vascular targeting. Nature Reviews 5:436-446.
19. Dunlap, S. M., J. Celestino, H. Wang, et al. 2007. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proceedings of the National Academy of Sciences of the United States of America 104:11736-11741.
20. Burgering, B. M., and P. J. Coffer. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602.
21. Franke, T. F., D. R. Kaplan, and L. C. Cantley. 1997. PI3K: downstream AKTion blocks apoptosis. Cell 88:435-437.
22. Franke, T. F., S. I. Yang, T. O. Chan, et al. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736.
23. Samuels, Y., Z. Wang, A. Bardelli, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
24. Schonleben, F., W. Qiu, H. E. Remotti, W. Hohenberger, and G. H. Su. 2008. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbeck's Archives Surgery 393:289-296.
25. Lu, Y., Q. Yu, J. H. Liu, et al. 2003. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. Journal of Biological Chemistry 278:40057-40066.
26. Puls, L. N., M. Eadens, and W. Messersmith. 2011. Current status of SRC inhibitors in solid tumor malignancies. The Oncologist 16:566-578.
27. Therasse, P., S. G. Arbuck, E. A. Eisenhauer, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92:205-216.
28. Jhawer, M., S. Goel, A. J. Wilson, et al. 2008. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Research 68:1953-1961.
29. Burris, H. A., III, S. Rivkin, R. Reynolds, et al. 2005. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. The Oncologist 10:183-190.
30. Baselga, J., A. Cervantes, E. Martinelli, et al. 2010. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clinical Cancer Research 16:4876-4883.
31. Renouf, D. J., M. J. Moore, D. Hedley, et al. 2010. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs 30:779-786.
32. Fury, M. G., S. Baxi, R. Shen, et al. 2011. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Research 31:249-253.
33. Gajewski, T. F., Y. Zha, and J. Clark. 2010. Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Journal of Clinical Oncology 28(15 suppl), abstr 8562.
34. Lara, P. N., Jr., J. Longmate, C. P. Evans, et al. 2009. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20:179-184.
35. Mackay, H. J., H. J. Au, E. McWhirter, et al. 2011. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investigational New Drugs 30:1158-1163.
36. Traina, T. A., J. A. Sparano, J. Caravelli, et al. 2010. Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). Journal of Clinical Oncology 28(15 suppl), abstr 1086.
37. Miled, N., Y. Yan, W. C. Hon, et al. 2007. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239-242.
38. Arcaroli, J. J., K. S. Quackenbush, R. W. Powell, et al. 2012. Common PIK3CA mutants and a novel 3′ UTR mutation are associated with increased sensitivity to saracatinib. Clinical Cancer Research 18:2704-2714.
39. von Ahlfen, S., A. Missel, K. Bendrat, and M. Schlumpberger. 2007. Determinants of RNA quality from FFPE samples. PLoS ONE 2:e1261.